{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:58:59Z","timestamp":1790279939800,"version":"4.1.0"},"reference-count":258,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03469-5","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:34:55Z","timestamp":1790235295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Recent Innovations in Drug Delivery Systems for Amyotrophic Lateral Sclerosis: Past, Present and Future"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-6847","authenticated-orcid":false,"given":"Dhvani P","family":"Padhiyar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9461-6612","authenticated-orcid":false,"given":"Shital","family":"Butani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5893-8454","authenticated-orcid":false,"given":"Tushar","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7702-477X","authenticated-orcid":false,"given":"Amit","family":"Mukharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2103-2127","authenticated-orcid":false,"given":"Amarjitsing","family":"Rajput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"3469_CR1","doi-asserted-by":"publisher","first-page":"102357","DOI":"10.1016\/j.arr.2024.102357","volume":"99","author":"DG Gadhave","year":"2024","unstructured":"Gadhave DG, Sugandhi VV, Jha SK, Nangare SN, Gupta G, Singh SK, et al. Neurodegenerative disorders: Mechanisms of degeneration and therapeutic approaches with their clinical relevance. Ageing Res Rev. 2024;99:102357. https:\/\/doi.org\/10.1016\/j.arr.2024.102357.","journal-title":"Ageing Res Rev"},{"key":"3469_CR2","doi-asserted-by":"publisher","unstructured":"Quigley SE, Quigg KH, Goutman SA. Genetic and mechanistic insights inform amyotrophic lateral sclerosis treatment and symptomatic management: Current and emerging therapeutics and clinical trial design considerations. CNS Drugs. 123AD;39:949\u2013993. https:\/\/doi.org\/10.1007\/s40263-025-01217-0.","DOI":"10.1007\/s40263-025-01217-0"},{"key":"3469_CR3","unstructured":"Brotman RG, Moreno-Escobar MC, Joseph J, Munakomi S, Pawar G. Amyotrophic Lateral Sclerosis. Published online February 12, 2024. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556151\/. Accessed 9 Nov 2025."},{"issue":"8","key":"3469_CR4","doi-asserted-by":"publisher","first-page":"e213467","DOI":"10.1212\/WNL.0000000000213467","volume":"104","author":"R Vasta","year":"2025","unstructured":"Vasta R, De Mattei F, Tafaro S, et al. Changes to Average Survival of Patients With Amyotrophic Lateral Sclerosis (1995\u20132018): Results From the Piemonte and Valle d\u2019Aosta Registry. Neurology. 2025;104(8):e213467. https:\/\/doi.org\/10.1212\/WNL.0000000000213467.","journal-title":"Neurology"},{"key":"3469_CR5","doi-asserted-by":"publisher","unstructured":"Barberio J, Lally C, Kupelian V, Hardiman O, Flanders WD. Estimated familial amyotrophic lateral sclerosis proportion. Neurol Genet. Published Online. 2023. https:\/\/doi.org\/10.1212\/nxg.0000000000200109.","DOI":"10.1212\/nxg.0000000000200109"},{"key":"3469_CR6","doi-asserted-by":"publisher","unstructured":"Jih KY, Fang SY, Lee YC. Advances in ALS genetics and emerging precision therapies. J Formosan Medical Assoc. Published online October 25, 2025. https:\/\/doi.org\/10.1016\/J.JFMA.2025.10.032.","DOI":"10.1016\/J.JFMA.2025.10.032"},{"key":"3469_CR7","doi-asserted-by":"publisher","unstructured":"Duan QQ, Jiang Z, Su WM, et al. Risk factors of amyotrophic lateral sclerosis: a global meta-summary. Front Neurosci. Published Online. 2023. https:\/\/doi.org\/10.3389\/fnins.2023.1177431.","DOI":"10.3389\/fnins.2023.1177431"},{"key":"3469_CR8","doi-asserted-by":"publisher","unstructured":"Lian L, Liu M, Cui L, et al. Environmental risk factors and amyotrophic lateral sclerosis (ALS): A case-control study of ALS in China. J Clin Neurosci. Published online. 2019. https:\/\/doi.org\/10.1016\/j.jocn.2019.05.036.","DOI":"10.1016\/j.jocn.2019.05.036"},{"key":"3469_CR9","doi-asserted-by":"publisher","unstructured":"Hinchcliffe M, Smith A. Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromusc Disease. Published online 2017. https:\/\/doi.org\/10.2147\/DNND.S135748.","DOI":"10.2147\/DNND.S135748"},{"key":"3469_CR10","doi-asserted-by":"publisher","unstructured":"Nourelden AZ, Kamal I, Hagrass AI, et al. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. Published online. 2023. https:\/\/doi.org\/10.1007\/s10072-023-06869-8.","DOI":"10.1007\/s10072-023-06869-8"},{"key":"3469_CR11","unstructured":"Amylyx Pharmaceuticals. Amylyx Pharmaceuticals Announces Formal Intention to Remove RELYVRIO\u00ae\/ALBRIOZA\u2122 from the Market; Provides Updates on Access to Therapy, Pipeline, Corporate Restructuring, and Strategy. Available at: https:\/\/www.amylyx.com\/news\/amylyx- pharmaceuticals-announces- formal- intention- to-remove-relyvrior\/ albriozatm- from- the-market- provides- updates- on- access- to- therapy- pipeline- corporate- restructuring- and- strategy. Accessed 9 Nov 2025."},{"key":"3469_CR12","unstructured":"U.S. Food and Drug Administration. FDA approves treatment of amyotrophic lateral sclerosis associated with a mutation in the SOD1 gene. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-amyotrophic-lateral-sclerosis-associated-mutation-sod1-gene. Accessed 9 Nov 2025."},{"key":"3469_CR13","doi-asserted-by":"publisher","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood\u2013brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Therapy. Published online 2023. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","DOI":"10.1038\/s41392-023-01481-w"},{"issue":"1","key":"3469_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12987-024-00565-1","volume":"21","author":"JM Wasielewska","year":"2024","unstructured":"Wasielewska JM, Chaves JCS, Cabral-da-Silva MC, et al. A patient-derived amyotrophic lateral sclerosis blood-brain barrier model for focused ultrasound-mediated anti-TDP-43 antibody delivery. Fluids Barri CNS. 2024;21(1):1\u201320. https:\/\/doi.org\/10.1186\/S12987-024-00565-1.","journal-title":"Fluids Barri CNS"},{"key":"3469_CR15","doi-asserted-by":"publisher","first-page":"1644633","DOI":"10.3389\/FDDEV.2025.1644633","volume":"5","author":"X Zhang","year":"2025","unstructured":"Zhang X, Fu M, Wang Y, Wu T. Strategies for delivering drugs across the blood-brain barrier for the treatment of neurodegenerative diseases. Front Drug Deliv. 2025;5:1644633. https:\/\/doi.org\/10.3389\/FDDEV.2025.1644633.","journal-title":"Front Drug Deliv"},{"issue":"1","key":"3469_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12951-024-02764-2","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Li F, Jia B, et al. Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement-coagulation cascade and NF-$$\\kappa $$B signaling in SOD1G93A mice. J Nanobiotechnol. 2024;22(1):1\u201322. https:\/\/doi.org\/10.1186\/S12951-024-02764-2.","journal-title":"J Nanobiotechnol"},{"key":"3469_CR17","doi-asserted-by":"publisher","unstructured":"Pokrishevsky E, Grad LI, Cashman NR. TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion. Scientif Rep. 2016;6. https:\/\/doi.org\/10.1038\/srep22155.","DOI":"10.1038\/srep22155"},{"key":"3469_CR18","doi-asserted-by":"publisher","unstructured":"Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Molecul Neurodegen. 2020;15(1). https:\/\/doi.org\/10.1186\/s13024-020-00397-1.","DOI":"10.1186\/s13024-020-00397-1"},{"issue":"4","key":"3469_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s10517-008-0124-4","volume":"145","author":"IA Zavalishin","year":"2008","unstructured":"Zavalishin IA, Bochkov NP, Suslina ZA, et al. Gene therapy of amyotrophic lateral sclerosis. Bull Exp Biol Med. 2008;145(4):483\u20136. https:\/\/doi.org\/10.1007\/s10517-008-0124-4.","journal-title":"Bull Exp Biol Med"},{"issue":"4","key":"3469_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/aps.2009.24","volume":"30","author":"XX Dong","year":"2009","unstructured":"Dong XX, Wang Y, Qin ZH. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol Sin. 2009;30(4):379\u201387. https:\/\/doi.org\/10.1038\/aps.2009.24.","journal-title":"Acta Pharmacol Sin"},{"issue":"8","key":"3469_CR21","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.bbabio.2016.04.003","volume":"1857","author":"CB Rueda","year":"2016","unstructured":"Rueda CB, Llorente-Folch I, Traba J, et al. Glutamate excitotoxicity and Ca2+-regulation of respiration: Role of the Ca2+-activated mitochondrial transporters (CaMCs). Biochimica et Biophysica Acta - Bioenergetics. 2016;1857(8):1158\u201366. https:\/\/doi.org\/10.1016\/j.bbabio.2016.04.003.","journal-title":"Biochimica et Biophysica Acta - Bioenergetics"},{"key":"3469_CR22","doi-asserted-by":"publisher","unstructured":"Ureshino RP, Erustes AG, Bassani TB, et al. The interplay between Ca2+ signaling pathways and neurodegeneration. Intern J Molecul Sci. 2019;20(23). https:\/\/doi.org\/10.3390\/ijms20236004.","DOI":"10.3390\/ijms20236004"},{"key":"3469_CR23","doi-asserted-by":"crossref","unstructured":"Verma M, Lizama BN, Chu CT. Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration. Transl Neurodegen. 2022;11(1). https:\/\/doi.org\/10.1186\/s40035-021-00278-7.","DOI":"10.1186\/s40035-021-00278-7"},{"key":"3469_CR24","doi-asserted-by":"publisher","unstructured":"Bonafede R, Mariotti R. ALS pathogenesis and therapeutic approaches: The role of mesenchymal stem cells and extracellular vesicles. Front Cellular Neurosci. Published online 2017. https:\/\/doi.org\/10.3389\/fncel.2017.00080.","DOI":"10.3389\/fncel.2017.00080"},{"key":"3469_CR25","doi-asserted-by":"publisher","unstructured":"van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: Insights from advances in neurophysiological techniques. Intern J Molecul Sci. Published online 2019. https:\/\/doi.org\/10.3390\/ijms20112818.","DOI":"10.3390\/ijms20112818"},{"key":"3469_CR26","doi-asserted-by":"publisher","unstructured":"Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Prim. Published online 2017. https:\/\/doi.org\/10.1038\/nrdp.2017.71.","DOI":"10.1038\/nrdp.2017.71"},{"key":"3469_CR27","doi-asserted-by":"publisher","unstructured":"Hemerkov\u00e1 P, Vali\u0161 M. Role of oxidative stress in the pathogenesis of amyotrophic lateral sclerosis: Antioxidant metalloenzymes and therapeutic strategies. Biomolecules. Published online 2021. https:\/\/doi.org\/10.3390\/biom11030437.","DOI":"10.3390\/biom11030437"},{"key":"3469_CR28","doi-asserted-by":"publisher","unstructured":"Guo CY, Sun L, Chen XP, Zhang DS. Oxidative stress, mitochondrial damage and neurodegenerative diseases. Neural Regener Res. Published online 2013. https:\/\/doi.org\/10.3969\/j.issn.1673-5374.2013.21.009.","DOI":"10.3969\/j.issn.1673-5374.2013.21.009"},{"key":"3469_CR29","doi-asserted-by":"publisher","unstructured":"Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Report. Published online 2016. https:\/\/doi.org\/10.1179\/1351000215Y.0000000026.","DOI":"10.1179\/1351000215Y.0000000026"},{"key":"3469_CR30","doi-asserted-by":"publisher","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Therapy. Published online 2023. https:\/\/doi.org\/10.1038\/s41392-023-01588-0.","DOI":"10.1038\/s41392-023-01588-0"},{"key":"3469_CR31","doi-asserted-by":"publisher","unstructured":"Rosenblum LT, Trotti D. EAAT2 and the molecular signature of amyotrophic lateral sclerosis. In: Advances in neurobiology. 2017. https:\/\/doi.org\/10.1007\/978-3-319-55769-4_6.","DOI":"10.1007\/978-3-319-55769-4_6"},{"key":"3469_CR32","doi-asserted-by":"publisher","unstructured":"Staats KA, Van Den Bosch L. Astrocytes in amyotrophic lateral sclerosis: Direct effects on motor neuron survival. J Biol Phys. Published online 2009. https:\/\/doi.org\/10.1007\/s10867-009-9141-4.","DOI":"10.1007\/s10867-009-9141-4"},{"key":"3469_CR33","doi-asserted-by":"publisher","unstructured":"Arnold FJ, Putka AF, Raychaudhuri U, et al. Revisiting glutamate excitotoxicity in amyotrophic lateral sclerosis and age-related neurodegeneration. Intern J Molecul Sci. 2024;25(11). https:\/\/doi.org\/10.3390\/ijms25115587.","DOI":"10.3390\/ijms25115587"},{"key":"3469_CR34","doi-asserted-by":"publisher","unstructured":"Grosskreutz J, Van Den Bosch L, Keller BU. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium. Published online 2010. https:\/\/doi.org\/10.1016\/j.ceca.2009.12.002.","DOI":"10.1016\/j.ceca.2009.12.002"},{"issue":"6","key":"3469_CR35","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2217\/nmt-2020-0033","volume":"10","author":"Y Saitoh","year":"2020","unstructured":"Saitoh Y, Takahashi Y. Riluzole for the treatment of amyotrophic lateral sclerosis. Neurodegener Dis Manage. 2020;10(6):343\u201355. https:\/\/doi.org\/10.2217\/nmt-2020-0033.","journal-title":"Neurodegener Dis Manage"},{"issue":"2","key":"3469_CR36","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1002\/med.21528","volume":"39","author":"MK Jaiswal","year":"2019","unstructured":"Jaiswal MK. Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev. 2019;39(2):733\u201348. https:\/\/doi.org\/10.1002\/med.21528.","journal-title":"Med Res Rev"},{"key":"3469_CR37","doi-asserted-by":"publisher","unstructured":"Ketabforoush AHME, Chegini R, Barati S, et al. Masitinib: The promising actor in the next season of the amyotrophic lateral sclerosis treatment series. Biomed Pharmacotherap. 2023;160. https:\/\/doi.org\/10.1016\/j.biopha.2023.114378.","DOI":"10.1016\/j.biopha.2023.114378"},{"issue":"2","key":"3469_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/1673-5374.200794","volume":"12","author":"S Mathis","year":"2017","unstructured":"Mathis S, Couratier P, Julian A, Corcia P, Le Masson G. Current view and perspectives in amyotrophic lateral sclerosis. Neural Regen Res. 2017;12(2):181\u20134. https:\/\/doi.org\/10.4103\/1673-5374.200794.","journal-title":"Neural Regen Res"},{"issue":"7","key":"3469_CR39","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/14737159.2020.1779060","volume":"20","author":"B Perrone","year":"2020","unstructured":"Perrone B, Conforti FL. Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn. 2020;20(7):703\u201314. https:\/\/doi.org\/10.1080\/14737159.2020.1779060.","journal-title":"Expert Rev Mol Diagn"},{"key":"3469_CR40","doi-asserted-by":"publisher","unstructured":"Khojasteh SC, Wong H, Hop CECA. Approved drugs. In: Drug metabolism and pharmacokinetics quick guide. https:\/\/doi.org\/10.1007\/978-1-4419-5629-3_11.","DOI":"10.1007\/978-1-4419-5629-3_11"},{"issue":"7","key":"3469_CR41","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s40267-016-0312-7","volume":"32","author":"GM Keating","year":"2016","unstructured":"Keating GM. Riluzole oral suspension in amyotrophic lateral sclerosis: a guide to its use. Drugs Therap Perspect. 2016;32(7):282\u20136. https:\/\/doi.org\/10.1007\/s40267-016-0312-7.","journal-title":"Drugs Therap Perspect"},{"issue":"7","key":"3469_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/ncpneuro0853","volume":"4","author":"P K\u00fchnlein","year":"2008","unstructured":"K\u00fchnlein P, Gdynia HJ, Sperfeld AD, et al. Diagnosis and treatment of bulbar symptoms in amyotrophic lateral sclerosis. Nat Clin Pract Neurol. 2008;4(7):366\u201374. https:\/\/doi.org\/10.1038\/ncpneuro0853.","journal-title":"Nat Clin Pract Neurol"},{"issue":"1","key":"3469_CR43","first-page":"25","volume":"43","author":"MP Cruz","year":"2018","unstructured":"Cruz MP. Edaravone (Radicava): A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. Pharm Therapeut. 2018;43(1):25\u20138.","journal-title":"Pharm Therapeut"},{"key":"3469_CR44","unstructured":"U.S. Food and Drug Administration. RADICAVA (edaravone injection), for intravenous use. Published online 2017:1\u201311. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209176lbl.pdf."},{"issue":"9","key":"3469_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/01.NAJ.0000874104.26408.02","volume":"122","author":"DS Aschenbrenner","year":"2022","unstructured":"Aschenbrenner DS. New oral form for ALS drug. Am J Nurs. 2022;122(9):24\u20135. https:\/\/doi.org\/10.1097\/01.NAJ.0000874104.26408.02.","journal-title":"Am J Nurs"},{"issue":"2","key":"3469_CR46","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/mus.27768","volume":"67","author":"A Genge","year":"2023","unstructured":"Genge A, Pattee GL, Sobue G, et al. Oral edaravone demonstrated a favorable safety profile in patients with amyotrophic lateral sclerosis after 48 weeks of treatment. Muscle Nerve. 2023;67(2):124\u20139. https:\/\/doi.org\/10.1002\/mus.27768.","journal-title":"Muscle Nerve"},{"issue":"3","key":"3469_CR47","doi-asserted-by":"publisher","first-page":"034","DOI":"10.30574\/gscbps.2020.11.3.0154","volume":"11","author":"ED Ekpa","year":"2020","unstructured":"Ekpa ED, Asuquo UR, Akpabio AE, Ime SNA, Uko AI. The oral film delivery: Application of nanotechnology and potential in medication adherence. GSC Biol Pharmaceut Sci. 2020;11(3):034\u201351. https:\/\/doi.org\/10.30574\/gscbps.2020.11.3.0154.","journal-title":"GSC Biol Pharmaceut Sci"},{"issue":"3","key":"3469_CR48","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/j3030021","volume":"3","author":"G Colombo","year":"2020","unstructured":"Colombo G, Artico R, Barbareschi D. Riluzole oral suspension for the treatment of amyotrophic lateral sclerosis: Texture and compatibility with food thickeners evaluation. Journal. 2020;3(3):275\u201388. https:\/\/doi.org\/10.3390\/j3030021.","journal-title":"Journal"},{"issue":"1","key":"3469_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/cpdd.1168","volume":"12","author":"J Wymer","year":"2023","unstructured":"Wymer J, Apple S, Harrison A, Hill BA. Pharmacokinetics, bioavailability, and swallowing safety with riluzole oral film. Clinical Pharmacol Drug Develop. 2023;12(1):57\u201364. https:\/\/doi.org\/10.1002\/cpdd.1168.","journal-title":"Clinical Pharmacol Drug Develop"},{"issue":"1","key":"3469_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14737175.2023.2174018","volume":"23","author":"Y Sun","year":"2023","unstructured":"Sun Y, Li X, Bedlack R. An evaluation of the combination of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2023;23(1):1\u20137. https:\/\/doi.org\/10.1080\/14737175.2023.2174018.","journal-title":"Expert Rev Neurother"},{"issue":"2","key":"3469_CR51","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/10600280231172802","volume":"58","author":"A Alqallaf","year":"2024","unstructured":"Alqallaf A, Cates DW, Render KP, Patel KA. Sodium phenylbutyrate and taurursodiol: A new therapeutic option for the treatment of amyotrophic lateral sclerosis. Ann Pharmacother. 2024;58(2):165\u201373. https:\/\/doi.org\/10.1177\/10600280231172802.","journal-title":"Ann Pharmacother"},{"issue":"11","key":"3469_CR52","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","volume":"83","author":"HA Blair","year":"2023","unstructured":"Blair HA. Tofersen: First approval. Drugs. 2023;83(11):1039\u201343. https:\/\/doi.org\/10.1007\/s40265-023-01904-6.","journal-title":"Drugs"},{"issue":"2","key":"3469_CR53","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1\u20132 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109\u201319. https:\/\/doi.org\/10.1056\/NEJMoa2003715.","journal-title":"N Engl J Med"},{"issue":"12","key":"3469_CR54","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med. 2022;387(12):1099\u2013110. https:\/\/doi.org\/10.1056\/NEJMoa2204705.","journal-title":"N Engl J Med"},{"issue":"5","key":"3469_CR55","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: A phase 1, randomised, first-in-man study. Lancet Neurol. 2013;12(5):435\u201342. https:\/\/doi.org\/10.1016\/S1474-4422(13)70061-9.","journal-title":"Lancet Neurol"},{"issue":"5","key":"3469_CR56","doi-asserted-by":"publisher","first-page":"7775","DOI":"10.3390\/molecules20057775","volume":"20","author":"N Nagoshi","year":"2015","unstructured":"Nagoshi N, Nakashima H, Fehlings MG. Riluzole as a neuroprotective drug for spinal cord injury: From bench to bedside. Molecules. 2015;20(5):7775\u201389. https:\/\/doi.org\/10.3390\/molecules20057775.","journal-title":"Molecules"},{"key":"3469_CR57","doi-asserted-by":"publisher","unstructured":"Mignani S, Majoral JP, Desaphy JF, Lentini G. From riluzole to dexpramipexole via substituted-benzothiazole derivatives for amyotrophic lateral sclerosis disease treatment: Case studies. Molecules. 2020;25(15). https:\/\/doi.org\/10.3390\/molecules25153320.","DOI":"10.3390\/molecules25153320"},{"key":"3469_CR58","doi-asserted-by":"publisher","unstructured":"Sever B, Ciftci H, Demirci H, et al. Comprehensive research on past and future therapeutic strategies devoted to treatment of amyotrophic lateral sclerosis. Intern J Molecul Sci. 2022;23(5). https:\/\/doi.org\/10.3390\/ijms23052400.","DOI":"10.3390\/ijms23052400"},{"issue":"1","key":"3469_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph14010029","volume":"14","author":"H Cho","year":"2021","unstructured":"Cho H, Shukla S. Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis. Pharmaceuticals. 2021;14(1):1\u201314. https:\/\/doi.org\/10.3390\/ph14010029.","journal-title":"Pharmaceuticals"},{"key":"3469_CR60","doi-asserted-by":"publisher","unstructured":"Jaiswal MK. Riluzole but not melatonin ameliorates acute motor neuron degeneration and moderately inhibits SOD1-mediated excitotoxicity induced disrupted mitochondrial Ca2+ signaling in amyotrophic lateral sclerosis. Front Cellular Neurosci. 2017;10. https:\/\/doi.org\/10.3389\/fncel.2016.00295.","DOI":"10.3389\/fncel.2016.00295"},{"key":"3469_CR61","doi-asserted-by":"publisher","unstructured":"Jaiswal M, Zech WD, Goos M, et al. Impairment of mitochondrial calcium handling in a mtSOD1 cell culture model of motoneuron disease. BMC Neurosci. 2009;10. https:\/\/doi.org\/10.1186\/1471-2202-10-64.","DOI":"10.1186\/1471-2202-10-64"},{"key":"3469_CR62","doi-asserted-by":"publisher","unstructured":"van den Bos MAJ, Geevasinga N, Higashihara M, Menon P, Vucic S. Pathophysiology and diagnosis of ALS: Insights from advances in neurophysiological techniques. Intern J Molecul Sci. 2019;20(11). https:\/\/doi.org\/10.3390\/ijms20112818.","DOI":"10.3390\/ijms20112818"},{"issue":"4","key":"3469_CR63","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2165\/00003495-199652040-00010","volume":"52","author":"HM Bryson","year":"1996","unstructured":"Bryson HM, Benfield P. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs. 1996;52(4):549\u201363. https:\/\/doi.org\/10.2165\/00003495-199652040-00010.","journal-title":"Drugs"},{"key":"3469_CR64","doi-asserted-by":"publisher","unstructured":"Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol. 2011. https:\/\/doi.org\/10.3389\/fphar.2011.00054.","DOI":"10.3389\/fphar.2011.00054"},{"issue":"9","key":"3469_CR65","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585\u201391. https:\/\/doi.org\/10.1056\/NEJM199403033300901.","journal-title":"N Engl J Med"},{"key":"3469_CR66","unstructured":"FirstWord Pharma. Mitsubishi withdraws EU filing for ALS drug Radicava as regulators request additional study. Available at: https:\/\/firstwordpharma.com\/story\/4798741. Accessed 10 July 2025."},{"key":"3469_CR67","doi-asserted-by":"publisher","unstructured":"Cha SJ, Kim K. Effects of edaravone, a drug approved for the treatment of amyotrophic lateral sclerosis, on mitochondrial function and neuroprotection. Antioxidants. 2022;11(2). https:\/\/doi.org\/10.3390\/antiox11020195.","DOI":"10.3390\/antiox11020195"},{"issue":"3","key":"3469_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discovery. 2023;22(3):185\u2013212. https:\/\/doi.org\/10.1038\/s41573-022-00612-2.","journal-title":"Nat Rev Drug Discovery"},{"issue":"10","key":"3469_CR69","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","volume":"44","author":"AZ Nourelden","year":"2023","unstructured":"Nourelden AZ, Kamal I, Hagrass AI, et al. Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci. 2023;44(10):3429\u201342. https:\/\/doi.org\/10.1007\/s10072-023-06869-8.","journal-title":"Neurol Sci"},{"issue":"3","key":"3469_CR70","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1179\/1351000215Y.0000000025","volume":"21","author":"A Fujisawa","year":"2016","unstructured":"Fujisawa A, Yamamoto Y. Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep. 2016;21(3):98\u2013103. https:\/\/doi.org\/10.1179\/1351000215Y.0000000025.","journal-title":"Redox Rep"},{"key":"3469_CR71","doi-asserted-by":"publisher","unstructured":"Minnelli C, Laudadio E, Galeazzi R, et al. Synthesis, characterization and antioxidant properties of a new lipophilic derivative of edaravone. Antioxidants. 2019;8(8). https:\/\/doi.org\/10.3390\/antiox8080258.","DOI":"10.3390\/antiox8080258"},{"key":"3469_CR72","doi-asserted-by":"crossref","unstructured":"Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyot Lateral Scleros Frontotemp Degener. 2017;18:5\u201310. https:\/\/doi.org\/10.1080\/21678421.2017.1353101.","DOI":"10.1080\/21678421.2017.1353101"},{"issue":"2","key":"3469_CR73","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.pjnns.2018.03.004","volume":"52","author":"M Ku\u017ama-Kozakiewicz","year":"2018","unstructured":"Ku\u017ama-Kozakiewicz M. Edaravone in the treatment of amyotrophic lateral sclerosis. Neurol Neurochir Pol. 2018;52(2):124\u20138. https:\/\/doi.org\/10.1016\/j.pjnns.2018.03.004.","journal-title":"Neurol Neurochir Pol"},{"issue":"10","key":"3469_CR74","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1517\/14656566.2010.493558","volume":"11","author":"PA Lapchak","year":"2010","unstructured":"Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753\u201363. https:\/\/doi.org\/10.1517\/14656566.2010.493558.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"3469_CR75","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3164\/jcbn.17-62","volume":"62","author":"K Watanabe","year":"2018","unstructured":"Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y. How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutrit. 2018;62(1):20\u201338. https:\/\/doi.org\/10.3164\/jcbn.17-62.","journal-title":"J Clin Biochem Nutrit"},{"issue":"10","key":"3469_CR76","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S, Macklin EA, Hendrix S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1916945.","journal-title":"N Engl J Med"},{"issue":"1","key":"3469_CR77","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.27091","volume":"63","author":"S Paganoni","year":"2021","unstructured":"Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021;63(1):31\u20139. https:\/\/doi.org\/10.1002\/mus.27091.","journal-title":"Muscle Nerve"},{"key":"3469_CR78","unstructured":"European Medicines Agency. Scientific conclusions and grounds for the suspension of the marketing authorisation presented by the European Medicines Agency. Published online 2013:1\u20132."},{"issue":"6","key":"3469_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/JCM9062004","volume":"9","author":"K Dhuri","year":"2020","unstructured":"Dhuri K, Bechtold C, Quijano E, et al. Antisense oligonucleotides: An emerging area in drug discovery and development. J Clin Med. 2020;9(6):1\u201324. https:\/\/doi.org\/10.3390\/JCM9062004.","journal-title":"J Clin Med"},{"issue":"6","key":"3469_CR80","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","volume":"94","author":"KM Schoch","year":"2017","unstructured":"Schoch KM, Miller TM. Antisense oligonucleotides: Translation from mouse models to human neurodegenerative diseases. Neuron. 2017;94(6):1056\u201370. https:\/\/doi.org\/10.1016\/j.neuron.2017.04.010.","journal-title":"Neuron"},{"issue":"18","key":"3469_CR81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21186807","volume":"21","author":"E Bernard","year":"2020","unstructured":"Bernard E, Pegat A, Svahn J, et al. Clinical and molecular landscape of ALS patients with SOD1 mutations: Novel pathogenic variants and novel phenotypes. Int J Mol Sci. 2020;21(18):1\u201311. https:\/\/doi.org\/10.3390\/ijms21186807.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3469_CR82","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1136\/jnnp-2016-313521","volume":"88","author":"T Bali","year":"2017","unstructured":"Bali T, Self W, Liu J, et al. Defining SOD1 ALS natural history to guide therapeutic clinical trial design. J Neurol Neurosurg Psychiat. 2017;88(2):99\u2013105. https:\/\/doi.org\/10.1136\/jnnp-2016-313521.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"3469_CR83","doi-asserted-by":"publisher","unstructured":"Huai J, Zhang Z. Structural properties and interaction partners of familial ALS-associated SOD1 mutants. Front Neurol. 2019;10. https:\/\/doi.org\/10.3389\/fneur.2019.00527.","DOI":"10.3389\/fneur.2019.00527"},{"key":"3469_CR84","doi-asserted-by":"publisher","unstructured":"Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database System Rev. Published online 2012. https:\/\/doi.org\/10.1002\/14651858.CD004156.pub4.","DOI":"10.1002\/14651858.CD004156.pub4"},{"key":"3469_CR85","doi-asserted-by":"publisher","unstructured":"Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). Neurology. Published online 2009. https:\/\/doi.org\/10.1212\/WNL.0b013e3181bc0141.","DOI":"10.1212\/WNL.0b013e3181bc0141"},{"key":"3469_CR86","volume-title":"Mexiletine for muscle cramps in ALS: A randomized double-blind crossover trial","author":"M Weiss","year":"2018","unstructured":"Weiss M, McDonald CM. Mexiletine for muscle cramps in ALS: A randomized double-blind crossover trial. Muscle & Nerve: Published online; 2018."},{"key":"3469_CR87","doi-asserted-by":"publisher","unstructured":"Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev. Published online 2012. https:\/\/doi.org\/10.1002\/14651858.CD004157.pub2.","DOI":"10.1002\/14651858.CD004157.pub2"},{"key":"3469_CR88","doi-asserted-by":"publisher","unstructured":"Garuti G, Rao F, Ribuffo V, Sansone VA. Sialorrhea in patients with ALS: current treatment options. Degener Neurol Neuromuscul Dis. Published online 2019. https:\/\/doi.org\/10.2147\/DNND.S168353.","DOI":"10.2147\/DNND.S168353"},{"key":"3469_CR89","doi-asserted-by":"publisher","unstructured":"Jost WH, B\u00e4umer T, Laskawi R, et al. Therapy of sialorrhea with botulinum neurotoxin. Neurol Therapy. Published online 2019. https:\/\/doi.org\/10.1007\/s40120-019-00155-6.","DOI":"10.1007\/s40120-019-00155-6"},{"key":"3469_CR90","doi-asserted-by":"publisher","unstructured":"Czell D, Bauer M, Binek J, Schoch OD, Weber M. Outcomes of percutaneous endoscopic gastrostomy tube insertion in respiratory-impaired amyotrophic lateral sclerosis patients under noninvasive ventilation. Respirat Care. Published online 2013. https:\/\/doi.org\/10.4187\/respcare.02024.","DOI":"10.4187\/respcare.02024"},{"key":"3469_CR91","doi-asserted-by":"publisher","unstructured":"Vianello A, Arcaro G, Palmieri A, et al. Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis. J Critic Care. Published online 2011. https:\/\/doi.org\/10.1016\/j.jcrc.2010.06.003.","DOI":"10.1016\/j.jcrc.2010.06.003"},{"key":"3469_CR92","doi-asserted-by":"publisher","unstructured":"Funo K, Negishi Y, Akamine C, Takeuchi R, Uzawa Y. Setting mechanical insufflation-exsufflation (MI-E) pressures for amyotrophic lateral sclerosis (ALS) patients to improve atelectasis and reduce risk of pneumothorax: A case report. Cureus. Published online 2022. https:\/\/doi.org\/10.7759\/cureus.25786.","DOI":"10.7759\/cureus.25786"},{"key":"3469_CR93","doi-asserted-by":"publisher","unstructured":"Dorst J, Ludolph AC. Non-invasive ventilation in amyotrophic lateral sclerosis. Therapeut Adv Neurol Disord. Published online 2019. https:\/\/doi.org\/10.1177\/1756286419857040.","DOI":"10.1177\/1756286419857040"},{"key":"3469_CR94","unstructured":"Cruz MP. Nuedexta for the treatment of pseudobulbar affect: A condition of involuntary crying or laughing. Pharmacy and Therapeutics. Published online 2013."},{"key":"3469_CR95","doi-asserted-by":"publisher","unstructured":"Pioro EP. Review of dextromethorphan 20 mg\/quinidine 10 mg (NUEDEXTA\u00ae) for pseudobulbar affect. Neurol Therap. Published online 2014. https:\/\/doi.org\/10.1007\/s40120-014-0018-5.","DOI":"10.1007\/s40120-014-0018-5"},{"key":"3469_CR96","doi-asserted-by":"publisher","unstructured":"Roos E, Mariosa D, Ingre C, et al. Depression in amyotrophic lateral sclerosis. Neurology. Published online 2016. https:\/\/doi.org\/10.1212\/WNL.0000000000002671.","DOI":"10.1212\/WNL.0000000000002671"},{"key":"3469_CR97","doi-asserted-by":"publisher","unstructured":"Van Damme P, Al-Chalabi A, Andersen PM, et al. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). European J Neurol. Published online 2024. https:\/\/doi.org\/10.1111\/ene.16264.","DOI":"10.1111\/ene.16264"},{"key":"3469_CR98","doi-asserted-by":"publisher","unstructured":"Kwak S. Pain in amyotrophic lateral sclerosis: a narrative review. J Yeungnam Med Sci. Published online 2022. https:\/\/doi.org\/10.12701\/jyms.2022.00332.","DOI":"10.12701\/jyms.2022.00332"},{"key":"3469_CR99","doi-asserted-by":"publisher","unstructured":"Rabkin JG, Gordon PH, McElhiney M, Rabkin R, Chew S, Mitsumoto H. Modafinil treatment of fatigue in patients with ALS: A placebo-controlled study. Muscle & Nerve. Published online 2009. https:\/\/doi.org\/10.1002\/mus.21245.","DOI":"10.1002\/mus.21245"},{"key":"3469_CR100","doi-asserted-by":"publisher","unstructured":"Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. Published online 2017. https:\/\/doi.org\/10.5664\/jcsm.6470.","DOI":"10.5664\/jcsm.6470"},{"key":"3469_CR101","doi-asserted-by":"publisher","unstructured":"Boentert M. Sleep disturbances in patients with amyotrophic lateral sclerosis: Current perspectives. Nat Sci Sleep. Published online 2019. https:\/\/doi.org\/10.2147\/NSS.S183504.","DOI":"10.2147\/NSS.S183504"},{"key":"3469_CR102","doi-asserted-by":"publisher","unstructured":"Tsai RM, Boxer AL. Treatment of frontotemporal dementia. Current Treatm Opt Neurol. Published online 2014. https:\/\/doi.org\/10.1007\/s11940-014-0319-0.","DOI":"10.1007\/s11940-014-0319-0"},{"key":"3469_CR103","doi-asserted-by":"publisher","unstructured":"Wang GY, Rayner SL, Chung R, Shi BY, Liang XJ. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Mater Today Bio. 2020;6. https:\/\/doi.org\/10.1016\/j.mtbio.2020.100055.","DOI":"10.1016\/j.mtbio.2020.100055"},{"issue":"2","key":"3469_CR104","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s13311-014-0332-8","volume":"12","author":"J Rosenfeld","year":"2015","unstructured":"Rosenfeld J, Strong MJ. Challenges in the understanding and treatment of amyotrophic lateral sclerosis\/motor neuron disease. Neurotherapeutics. 2015;12(2):317\u201325. https:\/\/doi.org\/10.1007\/s13311-014-0332-8.","journal-title":"Neurotherapeutics"},{"issue":"4","key":"3469_CR105","doi-asserted-by":"publisher","first-page":"314","DOI":"10.2174\/1570159X14666160120152423","volume":"14","author":"H Lu","year":"2016","unstructured":"Lu H, Le Dong W, Xie YY, Wang XP. Current therapy of drugs in amyotrophic lateral sclerosis. Curr Neuropharmacol. 2016;14(4):314\u201321. https:\/\/doi.org\/10.2174\/1570159X14666160120152423.","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"3469_CR106","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1111\/bph.15802","volume":"179","author":"Y Pan","year":"2022","unstructured":"Pan Y, Nicolazzo JA. Altered blood-brain barrier and blood-spinal cord barrier dynamics in amyotrophic lateral sclerosis: Impact on medication efficacy and safety. Br J Pharmacol. 2022;179(11):2577\u201388. https:\/\/doi.org\/10.1111\/bph.15802.","journal-title":"Br J Pharmacol"},{"key":"3469_CR107","doi-asserted-by":"publisher","unstructured":"Jiang T, Qin T, Gao P, et al. SIRT1 attenuates blood\u2013spinal cord barrier disruption after spinal cord injury by deacetylating p66Shc. Redox Biol. 2023;60. https:\/\/doi.org\/10.1016\/j.redox.2023.102615.","DOI":"10.1016\/j.redox.2023.102615"},{"key":"3469_CR108","doi-asserted-by":"publisher","unstructured":"Alajangi HK, Kaur M, Sharma A, et al. Blood\u2013brain barrier: Emerging trends on transport models and new-age strategies for therapeutic intervention against neurological disorders. Molecular Brain. 2022;15(1). https:\/\/doi.org\/10.1186\/s13041-022-00937-4.","DOI":"10.1186\/s13041-022-00937-4"},{"issue":"7","key":"3469_CR109","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.addr.2011.11.010","volume":"64","author":"Y Chen","year":"2012","unstructured":"Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev. 2012;64(7):640\u201365. https:\/\/doi.org\/10.1016\/j.addr.2011.11.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"3469_CR110","doi-asserted-by":"publisher","unstructured":"Bellettato CM, Scarpa M. Possible strategies to cross the blood\u2013brain barrier. Italian J Pediatrics. 2018;44. https:\/\/doi.org\/10.1186\/s13052-018-0563-0.","DOI":"10.1186\/s13052-018-0563-0"},{"issue":"9","key":"3469_CR111","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.2174\/1381612822666151221150733","volume":"22","author":"DS Hersh","year":"2016","unstructured":"Hersh DS, Wadajkar AS, Roberts NB, et al. Evolving drug delivery strategies to overcome the blood-brain barrier. Curr Pharm Des. 2016;22(9):1177\u201393. https:\/\/doi.org\/10.2174\/1381612822666151221150733.","journal-title":"Curr Pharm Des"},{"key":"3469_CR112","doi-asserted-by":"publisher","unstructured":"Kadry H, Noorani B, Cucullo L. A blood\u2013brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS. 2020;17(1). https:\/\/doi.org\/10.1186\/s12987-020-00230-3.","DOI":"10.1186\/s12987-020-00230-3"},{"key":"3469_CR113","doi-asserted-by":"publisher","unstructured":"Galea I. The blood-brain barrier in systemic infection and inflammation. Cellul Molecul Immunol. Published online 2021. https:\/\/doi.org\/10.1038\/s41423-021-00757-x.","DOI":"10.1038\/s41423-021-00757-x"},{"key":"3469_CR114","doi-asserted-by":"publisher","unstructured":"Bynoe MS, Viret C, Yan A, Kim DG. Adenosine receptor signaling: A key to opening the blood\u2013brain door. Fluids Barriers CNS. Published online 2015. https:\/\/doi.org\/10.1186\/s12987-015-0017-7.","DOI":"10.1186\/s12987-015-0017-7"},{"key":"3469_CR115","doi-asserted-by":"publisher","unstructured":"Zhao M, Ma J, Li M, et al. Cytochrome P450 enzymes and drug metabolism in humans. Intern J Molecul Sci. 2021;22(23). https:\/\/doi.org\/10.3390\/ijms222312808","DOI":"10.3390\/ijms222312808"},{"key":"3469_CR116","doi-asserted-by":"publisher","unstructured":"Kharasch ED. Principles of drug biotransformation. Anesth Pharmacol. 2011:72\u201389. https:\/\/doi.org\/10.1017\/cbo9780511781933.007.","DOI":"10.1017\/cbo9780511781933.007"},{"key":"3469_CR117","doi-asserted-by":"publisher","unstructured":"Aryal M, Fischer K, Gentile C, Gitto S, Zhang YZ, McDannold N. Effects on P-glycoprotein expression after blood\u2013brain barrier disruption using focused ultrasound and microbubbles. PLOS ONE. 2017;12(1). https:\/\/doi.org\/10.1371\/journal.pone.0166061.","DOI":"10.1371\/journal.pone.0166061"},{"key":"3469_CR118","doi-asserted-by":"publisher","unstructured":"Parikh A, Kathawala K, Tan CC, Garg S, Zhou XF. Development of a novel oral delivery system of edaravone for enhancing bioavailability. Intern J Pharmaceut. Published online 2016. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.10.052.","DOI":"10.1016\/j.ijpharm.2016.10.052"},{"key":"3469_CR119","doi-asserted-by":"publisher","unstructured":"Van Vliet EA, Iyer AM, Mesarosova L, et al. Expression and cellular distribution of P-glycoprotein and breast cancer resistance protein in amyotrophic lateral sclerosis patients. J Neuropathol Exper Neurol. Published online 2020. https:\/\/doi.org\/10.1093\/jnen\/nlz142.","DOI":"10.1093\/jnen\/nlz142"},{"key":"3469_CR120","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejps.2018.04.026","volume":"120","author":"T Yang","year":"2018","unstructured":"Yang T, Ferrill L, Gallant L, et al. Verapamil and riluzole cocktail liposomes overcome pharmacoresistance by inhibiting P-glycoprotein in brain endothelial and astrocyte cells: A potent approach to treat amyotrophic lateral sclerosis. Eur J Pharm Sci. 2018;120:30\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2018.04.026.","journal-title":"Eur J Pharm Sci"},{"key":"3469_CR121","doi-asserted-by":"publisher","unstructured":"Jablonski MR, Markandaiah SS, Jacob D, et al. Inhibiting drug efflux transporters improves efficacy of ALS therapeutics. Ann Clin Transl Neurol. Published online 2014. https:\/\/doi.org\/10.1002\/acn3.141.","DOI":"10.1002\/acn3.141"},{"key":"3469_CR122","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3389\/fneur.2017.00094","volume":"8","author":"E Onesti","year":"2017","unstructured":"Onesti E, Schettino I, Gori MC, Frasca V, Ceccanti M, Cambieri C, et al. Dysphagia in amyotrophic lateral sclerosis: impact on patient behavior, diet adaptation, and riluzole management. Front Neurol. 2017;8:94.","journal-title":"Front Neurol"},{"key":"3469_CR123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.58986\/al.2025.23611","volume":"2","author":"A-S Eriksson","year":"2025","unstructured":"Eriksson A-S, Johansson K. Dysphagia in Amyotrophic Lateral Sclerosis (ALS): The role of the ALS team to facilitate patient participation in dysphagia interventions. Acta Logopaedica. 2025;2:1\u201319.","journal-title":"Acta Logopaedica"},{"key":"3469_CR124","doi-asserted-by":"crossref","unstructured":"Introna A, D\u2019Errico E, Modugno B, Scarafino A, Fraddosio A, Distaso E, et al. Adherence to riluzole in patients with amyotrophic lateral sclerosis: an observational study. Neuropsychiatr Dis Treat. 2018:193\u2013203.","DOI":"10.2147\/NDT.S150550"},{"issue":"5","key":"3469_CR125","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/jnnp-2016-314661","volume":"88","author":"J Rooney","year":"2017","unstructured":"Rooney J, Burke T, Vajda A, Heverin M, Hardiman O. What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiat. 2017;88(5):381\u20135.","journal-title":"J Neurol Neurosurg Psychiat"},{"key":"3469_CR126","doi-asserted-by":"crossref","unstructured":"Ramamoorthy D, Severson K, Ghosh S, Sachs K, Glass JD, Fournier CN, Pooled Resource Open-Access ALS Clinical Trials Consortium Sherman Alexander 5, Herrington TM, Berry JD. Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data. Nat Computat Sci 2022;2(9):605\u2013616.","DOI":"10.1101\/2021.05.13.21254848"},{"issue":"1","key":"3469_CR127","doi-asserted-by":"publisher","first-page":"12408","DOI":"10.1038\/ncomms12408","volume":"7","author":"KC Arthur","year":"2016","unstructured":"Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. 2016;7(1):12408.","journal-title":"Nat Commun"},{"key":"3469_CR128","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/B978-0-12-802973-2.00013-6","volume":"138","author":"EO Talbott","year":"2016","unstructured":"Talbott EO, Malek AM, Lacomis D. The epidemiology of amyotrophic lateral sclerosis. Handb Clin Neurol. 2016;138:225\u201338.","journal-title":"Handb Clin Neurol"},{"key":"3469_CR129","doi-asserted-by":"crossref","unstructured":"McFarlane R , Ross R, Domhnaill \u00c9M, Chi\u00f2 A, Corcia P, Ingre C, McDermott CJ, et al. Dynamic modelling of the ALSFRS-R: leveraging population-based scores using neural networks. EBioMedicine 2025:122.","DOI":"10.1016\/j.ebiom.2025.106029"},{"key":"3469_CR130","doi-asserted-by":"publisher","unstructured":"Sanadgol N, Abedi M, Hashemzaei M, et al. Exosomes as nanocarriers for brain-targeted delivery of therapeutic nucleic acids: Advances and challenges. J Nanobiotechnol. 2025;23(1). https:\/\/doi.org\/10.1186\/s12951-025-03528-2.","DOI":"10.1186\/s12951-025-03528-2"},{"key":"3469_CR131","doi-asserted-by":"publisher","unstructured":"Xia X, Wang Y, Zheng JC. Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases. Transl Neurodegener. Published online 2022. https:\/\/doi.org\/10.1186\/s40035-022-00330-0.","DOI":"10.1186\/s40035-022-00330-0"},{"issue":"1","key":"3469_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40035-024-00453-6","volume":"13","author":"L Wang","year":"2024","unstructured":"Wang L, Zhang X, Yang Z, et al. Extracellular vesicles: Biological mechanisms and emerging therapeutic opportunities in neurodegenerative diseases. Transl Neurodegener. 2024;13(1):1\u201325. https:\/\/doi.org\/10.1186\/s40035-024-00453-6.","journal-title":"Transl Neurodegener"},{"key":"3469_CR133","doi-asserted-by":"publisher","unstructured":"Gschwendtberger T, Thau-Habermann N, von der Ohe J, Luo T, Hass R, Petri S. Protective effects of EVs\/exosomes derived from permanently growing human mesenchymal stem cells on primary murine ALS motor neurons. Neurosci Lett. Published online 2023. https:\/\/doi.org\/10.1016\/j.neulet.2023.137493.","DOI":"10.1016\/j.neulet.2023.137493"},{"key":"3469_CR134","doi-asserted-by":"publisher","unstructured":"Bonafede R, Turano E, Scambi I, Busato A, Bontempi P, Virla F, Schiaffino L, Marzola P, Bonetti B, Mariotti R. ASC-Exosomes Ameliorate the Disease Progression in SOD1(G93A) Murine Model Underlining Their Potential Therapeutic Use in Human ALS. Intern J Molecul Sci. Published online 2020. https:\/\/doi.org\/10.3390\/ijms21103651.","DOI":"10.3390\/ijms21103651"},{"key":"3469_CR135","doi-asserted-by":"publisher","unstructured":"Wang K, Li Y, Ren C, Wang Y, He W, Jiang Y. Extracellular Vesicles as Innovative Treatment Strategy for Amyotrophic Lateral Sclerosis. Front Cell Developm Biol. Published online 2021. https:\/\/doi.org\/10.3389\/fcell.2021.754630.","DOI":"10.3389\/fcell.2021.754630"},{"key":"3469_CR136","doi-asserted-by":"publisher","first-page":"1583992","DOI":"10.3389\/fmolb.2025.1583992","volume":"12","author":"G Schwarz","year":"2025","unstructured":"Schwarz G, Ren X, Xie W, Guo H, Jiang Y, Zhang J. Engineered exosomes: A promising drug delivery platform with therapeutic potential. Front Mol Biosci. 2025;12:1583992.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"3469_CR137","doi-asserted-by":"publisher","first-page":"478","DOI":"10.4103\/NRR.NRR-D-24-00720","volume":"21","author":"H Chen","year":"2026","unstructured":"Chen H, Li N, Cai Y, Ma C, Ye Y, Shi X, et al. Exosomes in neurodegenerative diseases: Therapeutic potential and modification methods. Neural Regen Res. 2026;21(2):478\u201390.","journal-title":"Neural Regen Res"},{"key":"3469_CR138","doi-asserted-by":"publisher","unstructured":"Zhou J, Li F, Jia B, Wu Z, Huang Z, He M, et al. Intranasal delivery of small extracellular vesicles reduces the progress of amyotrophic lateral sclerosis and the overactivation of complement-coagulation cascade and NF-$$\\kappa $$B signaling in SOD1$$^{G93A}$$ mice. J Nanobiotechnol. Published online 2024. https:\/\/doi.org\/10.1186\/s12951-024-02764-2.","DOI":"10.1186\/s12951-024-02764-2"},{"issue":"April","key":"3469_CR139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2025.1496304","volume":"16","author":"H Shen","year":"2025","unstructured":"Shen H, Chen J, Liu M, et al. Research progress of extracellular vesicles derived from mesenchymal stem cells in the treatment of neurodegenerative diseases. Front Immunol. 2025;16(April):1\u201312. https:\/\/doi.org\/10.3389\/fimmu.2025.1496304.","journal-title":"Front Immunol"},{"key":"3469_CR140","doi-asserted-by":"publisher","unstructured":"D\u00edaz-Garc\u00eda D, Ferrer-Donato \u00c1, M\u00e9ndez-Arriaga JM, et al. Design of mesoporous silica nanoparticles for the treatment of amyotrophic lateral sclerosis (ALS) with a therapeutic cocktail based on leptin and pioglitazone. ACS Biomater Sci Eng. Published online 2022. https:\/\/doi.org\/10.1021\/acsbiomaterials.2c00865.","DOI":"10.1021\/acsbiomaterials.2c00865"},{"key":"3469_CR141","doi-asserted-by":"publisher","unstructured":"Leyton-Jaimes MF, Ivert P, Hoeber J, et al. Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS. Scientif Rep. Published online 2020. https:\/\/doi.org\/10.1038\/s41598-020-77578-x.","DOI":"10.1038\/s41598-020-77578-x"},{"key":"3469_CR142","doi-asserted-by":"publisher","unstructured":"Shen H, Chen J, Liu M, Zhao M, Hu D, Xie F, et al. Research Progress of Extracellular Vesicles Derived from Mesenchymal Stem Cells in the Treatment of Neurodegenerative Diseases. Front Immunol. Published online 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1496304.","DOI":"10.3389\/fimmu.2025.1496304"},{"key":"3469_CR143","doi-asserted-by":"publisher","unstructured":"Marton S, Miquel E, Acosta-Rodr\u00edguez J, Fontenla S, Libisch G, Cassina P. SOD1$$^{G93A}$$ Astrocyte-Derived Extracellular Vesicles Induce Motor Neuron Death by a miRNA-155-5p-Mediated Mechanism. ASN Neuro. Published online 2023. https:\/\/doi.org\/10.1177\/17590914231197527.","DOI":"10.1177\/17590914231197527"},{"key":"3469_CR144","doi-asserted-by":"publisher","unstructured":"Logan A, Belli A, Di Pietro V, et al. The mechanism of action of a novel neuroprotective low molecular weight dextran sulphate: New platform therapy for neurodegenerative diseases like amyotrophic lateral sclerosis. Front Pharmacol. Published online 2022. https:\/\/doi.org\/10.3389\/fphar.2022.983853.","DOI":"10.3389\/fphar.2022.983853"},{"issue":"7","key":"3469_CR145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0291285","volume":"19","author":"V Srinivasan","year":"2024","unstructured":"Srinivasan V, Homer V, Barton D, et al. A low molecular weight dextran sulphate, ILB\u00ae, for the treatment of amyotrophic lateral sclerosis (ALS): An open-label, single-arm, single-centre, phase II trial. PLoS ONE. 2024;19(7):1\u201324. https:\/\/doi.org\/10.1371\/journal.pone.0291285.","journal-title":"PLoS ONE"},{"key":"3469_CR146","doi-asserted-by":"publisher","unstructured":"Fang T, Al Khleifat A, Meurgey JH, et al. Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study. Lancet Neurol. Published online 2018. https:\/\/doi.org\/10.1016\/S1474-4422(18)30054-1.","DOI":"10.1016\/S1474-4422(18)30054-1"},{"key":"3469_CR147","doi-asserted-by":"publisher","unstructured":"Brooks BR, Berry JD, Ciepielewska M, et al. Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis. eClinicalMedicine. Published online 2022. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101590.","DOI":"10.1016\/j.eclinm.2022.101590"},{"key":"3469_CR148","doi-asserted-by":"publisher","unstructured":"Paganoni S, Hendrix S, Dickson SP, et al. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. Published online 2021. https:\/\/doi.org\/10.1002\/mus.27091.","DOI":"10.1002\/mus.27091"},{"key":"3469_CR149","doi-asserted-by":"publisher","unstructured":"Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. New England J Med. Published online 2022. https:\/\/doi.org\/10.1056\/NEJMoa2204705.","DOI":"10.1056\/NEJMoa2204705"},{"key":"3469_CR150","doi-asserted-by":"publisher","unstructured":"Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-Mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Molecul Therap. Published online 2013. https:\/\/doi.org\/10.1038\/mt.2013.211.","DOI":"10.1038\/mt.2013.211"},{"key":"3469_CR151","doi-asserted-by":"publisher","unstructured":"Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: A randomised controlled trial. Lancet Neurol. Published online 2006. https:\/\/doi.org\/10.1016\/S1474-4422(05)70326-4.","DOI":"10.1016\/S1474-4422(05)70326-4"},{"issue":"6","key":"3469_CR152","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.3390\/neurolint16060101","volume":"16","author":"E Magni","year":"2024","unstructured":"Magni E, Hochsprung A, C\u00e1ceres-Matos R, et al. Effects of respiratory training on pulmonary function, cough, and functional independence in patients with amyotrophic lateral sclerosis. Neurol Int. 2024;16(6):1332\u201342. https:\/\/doi.org\/10.3390\/neurolint16060101.","journal-title":"Neurol Int"},{"key":"3469_CR153","doi-asserted-by":"publisher","unstructured":"Sancho J, Servera E, D\u00edaz J, Mar\u00edn J. Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest. Published online 2004. https:\/\/doi.org\/10.1378\/chest.125.4.1400.","DOI":"10.1378\/chest.125.4.1400"},{"key":"3469_CR154","doi-asserted-by":"publisher","unstructured":"Plowman EK, Gray LT, Chapin J, et al. Respiratory strength training in amyotrophic lateral sclerosis: A double-blind, randomized, multicenter, sham-controlled trial. Neurology. Published online 2023. https:\/\/doi.org\/10.1212\/WNL.0000000000206830.","DOI":"10.1212\/WNL.0000000000206830"},{"key":"3469_CR155","doi-asserted-by":"publisher","unstructured":"Muscaritoli M, Kushta I, Molfino A, Inghilleri M, Sabatelli M, Rossi FF. Nutritional and metabolic support in patients with amyotrophic lateral sclerosis. Nutrition. Published online 2012. https:\/\/doi.org\/10.1016\/j.nut.2012.01.011.","DOI":"10.1016\/j.nut.2012.01.011"},{"key":"3469_CR156","doi-asserted-by":"publisher","unstructured":"Ansari U, Wen J, Taguinod I, Nadora D, Nadora D, Lui F. Exploring dietary approaches in the prevention and management of amyotrophic lateral sclerosis: A literature review. AIMS Neurosci. Published online 2023. https:\/\/doi.org\/10.3934\/NEUROSCIENCE.2023028.","DOI":"10.3934\/NEUROSCIENCE.2023028"},{"key":"3469_CR157","doi-asserted-by":"publisher","unstructured":"Mora JS, Bradley WG, Chaverri D, et al. Long-term survival analysis of masitinib in amyotrophic lateral sclerosis. Therapeut Adv Neurol Disord. Published online 2021. https:\/\/doi.org\/10.1177\/17562864211030365.","DOI":"10.1177\/17562864211030365"},{"key":"3469_CR158","doi-asserted-by":"publisher","unstructured":"Berry JD, Cudkowicz ME, Windebank AJ, et al. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results. Neurology. Published online 2019. https:\/\/doi.org\/10.1212\/WNL.0000000000008620.","DOI":"10.1212\/WNL.0000000000008620"},{"key":"3469_CR159","doi-asserted-by":"publisher","unstructured":"Ionescu A, Gradus T, Altman T, et al. Targeting the sigma-1 receptor via pridopidine ameliorates central features of ALS pathology in a SOD1G93A model. Cell Death Dis. 2019;10(3). https:\/\/doi.org\/10.1038\/s41419-019-1451-2.","DOI":"10.1038\/s41419-019-1451-2"},{"key":"3469_CR160","doi-asserted-by":"publisher","unstructured":"Chi\u00f2 A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: A critical review. Amyotroph Lateral Scleros. Published online 2009. https:\/\/doi.org\/10.3109\/17482960802566824.","DOI":"10.3109\/17482960802566824"},{"key":"3469_CR161","doi-asserted-by":"publisher","unstructured":"Rooney J, Byrne S, Heverin M, et al. A multidisciplinary clinic approach improves survival in ALS: A comparative study of ALS in Ireland and Northern Ireland. J Neurol Neurosurg Psychiat. Published online 2015. https:\/\/doi.org\/10.1136\/jnnp-2014-309601.","DOI":"10.1136\/jnnp-2014-309601"},{"key":"3469_CR162","doi-asserted-by":"publisher","unstructured":"Chi\u00f2 A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G. Tracheostomy in amyotrophic lateral sclerosis: A 10-year population-based study in Italy. J Neurol Neurosurg Psychiat. Published online 2010. https:\/\/doi.org\/10.1136\/jnnp.2009.175984.","DOI":"10.1136\/jnnp.2009.175984"},{"issue":"4","key":"3469_CR163","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/pharmaceutics14040883","volume":"14","author":"SZ Alshawwa","year":"2022","unstructured":"Alshawwa SZ, Kassem AA, Farid RM, Mostafa SK, Labib GS. Nanocarrier drug delivery systems: characterization, limitations, future perspectives and implementation of artificial intelligence. Pharmaceutics. 2022;14(4):883.","journal-title":"Pharmaceutics"},{"issue":"1","key":"3469_CR164","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/10717544.2020.1748758","volume":"27","author":"W Meng","year":"2020","unstructured":"Meng W, He C, Hao Y, Wang L, Li L, Zhu G. Prospects and challenges of extracellular vesicle-based drug delivery system: considering cell source. Drug Deliv. 2020;27(1):585\u201398.","journal-title":"Drug Deliv"},{"key":"3469_CR165","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jconrel.2023.06.001","volume":"359","author":"Y Lu","year":"2023","unstructured":"Lu Y, Wang JTW, Li N, et al. Intranasal administration of edaravone nanoparticles improves its stability and brain bioavailability. J Control Release. 2023;359:257\u201367. https:\/\/doi.org\/10.1016\/j.jconrel.2023.06.001.","journal-title":"J Control Release"},{"key":"3469_CR166","doi-asserted-by":"publisher","unstructured":"Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR. Nanoparticles for targeted brain drug delivery: What do we know? Intern J Molecul Sci. 2021;22(21). https:\/\/doi.org\/10.3390\/ijms222111654.","DOI":"10.3390\/ijms222111654"},{"key":"3469_CR167","doi-asserted-by":"crossref","unstructured":"Bhuiyan P, Yi Y, Wei B, Yan A, Dong L, Wei H. Intranasal dantrolene nanoparticles for treatment of amyotrophic lateral sclerosis as a disease-modifying drug. bioRxiv. 2025.","DOI":"10.1101\/2025.05.21.655232"},{"issue":"1","key":"3469_CR168","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2217\/nnm.09.67","volume":"5","author":"ML Bond\u00ec","year":"2010","unstructured":"Bond\u00ec ML, Craparo EF, Giammona G, Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution. Nanomedicine. 2010;5(1):25\u201332. https:\/\/doi.org\/10.2217\/nnm.09.67.","journal-title":"Nanomedicine"},{"key":"3469_CR169","doi-asserted-by":"publisher","unstructured":"Teixeira MI, Lopes CM, Gon\u00e7alves H, et al. Formulation, characterization, and cytotoxicity evaluation of lactoferrin functionalized lipid nanoparticles for riluzole delivery to the brain. Pharmaceutics. 2022;14(1). https:\/\/doi.org\/10.3390\/pharmaceutics14010185.","DOI":"10.3390\/pharmaceutics14010185"},{"key":"3469_CR170","doi-asserted-by":"publisher","unstructured":"Teixeira MI, Lopes CM, Gon\u00e7alves H, et al. Riluzole-loaded lipid nanoparticles for brain delivery: Preparation, optimization and characterization. J Molecul Liq. 2023;388. https:\/\/doi.org\/10.1016\/j.molliq.2023.122749.","DOI":"10.1016\/j.molliq.2023.122749"},{"key":"3469_CR171","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2147\/DDDT.S161940","volume":"12","author":"A Parikh","year":"2018","unstructured":"Parikh A, Kathawala K, Tan CC, Garg S, Zhou XF. Self-nanomicellizing solid dispersion of edaravone: Part I - Oral bioavailability improvement. Drug Des Dev Ther. 2018;12:2051\u201369. https:\/\/doi.org\/10.2147\/DDDT.S161940.","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"3469_CR172","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1080\/10717544.2017.1337825","volume":"24","author":"A Parikh","year":"2017","unstructured":"Parikh A, Kathawala K, Tan CC, Garg S, Zhou XF. Lipid-based nanosystem of edaravone: Development, optimization, characterization and in vitro\/in vivo evaluation. Drug Deliv. 2017;24(1):962\u201378. https:\/\/doi.org\/10.1080\/10717544.2017.1337825.","journal-title":"Drug Deliv"},{"issue":"3","key":"3469_CR173","doi-asserted-by":"publisher","first-page":"319","DOI":"10.25004\/ijpsdr.2022.140303","volume":"14","author":"GB Patil","year":"2022","unstructured":"Patil GB, Patil PB, Sonar AP, Mahajan MR, Patil JH, Patil DA. Formulation and characterization of edaravone-loaded chitosan nanoparticles for treatment of amyotrophic lateral sclerosis. Intern J Pharmaceut Sci Drug Res. 2022;14(3):319\u201327. https:\/\/doi.org\/10.25004\/ijpsdr.2022.140303.","journal-title":"Intern J Pharmaceut Sci Drug Res"},{"key":"3469_CR174","doi-asserted-by":"publisher","unstructured":"Niccolini B, Palmieri V, De Spirito M, Papi M. Opportunities offered by graphene nanoparticles for microRNAs delivery for amyotrophic lateral sclerosis treatment. Materials (Basel). Published online 2022. https:\/\/doi.org\/10.3390\/ma15010126.","DOI":"10.3390\/ma15010126"},{"key":"3469_CR175","doi-asserted-by":"publisher","unstructured":"Naseri N, Valizadeh H, Zakeri-Milani P. Solid lipid nanoparticles and nanostructured lipid carriers: Structure, preparation and application. Adv Pharmaceut Bull. Published online 2015. https:\/\/doi.org\/10.15171\/apb.2015.043.","DOI":"10.15171\/apb.2015.043"},{"key":"3469_CR176","doi-asserted-by":"publisher","unstructured":"Duan Y, Dhar A, Patel C, et al. A brief review on solid lipid nanoparticles: Part and parcel of contemporary drug delivery systems. RSC Adv. Published online 2020. https:\/\/doi.org\/10.1039\/d0ra03491f.","DOI":"10.1039\/d0ra03491f"},{"issue":"9","key":"3469_CR177","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.jsps.2021.07.015","volume":"29","author":"M Elmowafy","year":"2021","unstructured":"Elmowafy M, Al-Sanea MM. Nanostructured lipid carriers (NLCs) as drug delivery platforms: Advances in formulation and delivery strategies. Saudi Pharmaceut J. 2021;29(9):999\u20131012. https:\/\/doi.org\/10.1016\/j.jsps.2021.07.015.","journal-title":"Saudi Pharmaceut J"},{"key":"3469_CR178","doi-asserted-by":"publisher","unstructured":"Mushtaq A, Mohd Wani S, Malik AR, et al. Recent insights into nanoemulsions: Their preparation, properties and applications. Food Chem X. Published online 2023. https:\/\/doi.org\/10.1016\/j.fochx.2023.100684.","DOI":"10.1016\/j.fochx.2023.100684"},{"key":"3469_CR179","doi-asserted-by":"publisher","unstructured":"Malode GP, Ande SN, Chavhan SA, et al. A critical review on nanoemulsions: Advantages, techniques and characterization. World J Adv Res Rev. Published online 2021. https:\/\/doi.org\/10.30574\/wjarr.2021.11.3.0431.","DOI":"10.30574\/wjarr.2021.11.3.0431"},{"key":"3469_CR180","doi-asserted-by":"publisher","unstructured":"Aljabri NM, Shi N, Cavazos A. Nanoemulsion: An emerging technology for oilfield applications between limitations and potentials. J Petrol Sci Eng. Published online 2022. https:\/\/doi.org\/10.1016\/j.petrol.2021.109306.","DOI":"10.1016\/j.petrol.2021.109306"},{"key":"3469_CR181","doi-asserted-by":"publisher","unstructured":"Chis AC, Dobrea C, Morgovan C, et al. Applications and limitations of dendrimers in biomedicine. Molecules. Published online 2020. https:\/\/doi.org\/10.3390\/molecules25173982.","DOI":"10.3390\/molecules25173982"},{"key":"3469_CR182","doi-asserted-by":"publisher","unstructured":"Xu L, Zhang H, Wu Y. Dendrimer advances for the central nervous system delivery of therapeutics. ACS Chem Neurosci. Published online 2014. https:\/\/doi.org\/10.1021\/cn400182z.","DOI":"10.1021\/cn400182z"},{"key":"3469_CR183","doi-asserted-by":"publisher","unstructured":"Alavian F, Shams N. Oral and intranasal administration of nanoparticles in the cerebral ischemia treatment in animal experiments: Advantages and disadvantages. Curr Clin Pharmacol. Published online 2019. https:\/\/doi.org\/10.2174\/1574884714666190704115345.","DOI":"10.2174\/1574884714666190704115345"},{"key":"3469_CR184","doi-asserted-by":"publisher","unstructured":"Zorkina Y, Abramova O, Ushakova V, et al. Nanocarrier drug delivery systems for the treatment of neuropsychiatric disorders: Advantages and limitations. Molecules. Published online 2020. https:\/\/doi.org\/10.3390\/molecules25225294.","DOI":"10.3390\/molecules25225294"},{"key":"3469_CR185","doi-asserted-by":"publisher","unstructured":"Patel T, Zhou J, Piepmeier JM, Saltzman WM. Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev. Published online 2012. https:\/\/doi.org\/10.1016\/j.addr.2011.12.006.","DOI":"10.1016\/j.addr.2011.12.006"},{"key":"3469_CR186","unstructured":"Garc\u00eda-Corvillo MDP. Polymeric nanoparticles for drug delivery to the central nervous system via nasal route. Ars Pharmaceutica: Published online 2016."},{"key":"3469_CR187","unstructured":"World Intellectual Property Organization. Riluzole aqueous suspensions. Patent WO2010102923A2. Available at: https:\/\/patents.google.com\/patent\/WO2010102923A2\/en. Accessed 23 Jan 2024."},{"key":"3469_CR188","unstructured":"United States Patent and Trademark Office. Liquid suspension for oral administration. Patent US5156842A. Available at: https:\/\/patents.google.com\/patent\/US5156842A\/en. Accessed 23 Jan 2024"},{"key":"3469_CR189","unstructured":"Drago F, Giammona G. Nanostructured lipid carriers containing riluzole and pharmaceutical formulations containing said particles. Patent WO2008000448A2. Available at: https:\/\/patents.google.com\/patent\/WO2008000448A2\/en. Accessed 23 Jan 2024."},{"key":"3469_CR190","unstructured":"World Intellectual Property Organization. WO2010113225A1. Accessed 23 Jan 2024."},{"key":"3469_CR191","unstructured":"World Intellectual Property Organization. Edaravone pharmaceutical composition. Patent WO2019205700A1. Available at: https:\/\/patents.google.com\/patent\/WO2019205700A1\/en. Accessed 23 Jan 2024."},{"key":"3469_CR192","unstructured":"O\u2019Riordan C, Wadsworth S. Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders. US Patent 9890394B2. 2018. Available at: https:\/\/patents.google.com\/patent\/US9890394B2\/en. Accessed 23 Jan 2024."},{"key":"3469_CR193","unstructured":"United States Patent and Trademark Office. Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast. Patent US9314452B2. Available at: https:\/\/patents.google.com\/patent\/US9314452B2\/en. Accessed 23 Jan 2024."},{"key":"3469_CR194","unstructured":"World Intellectual Property Organization. Treatment comprising oral or gastric administration of edaravone. Patent WO2018134243A1. Available at: https:\/\/patents.google.com\/patent\/WO2018134243A1\/en. Accessed 23 Jan 2024."},{"key":"3469_CR195","unstructured":"World Intellectual Property Organization. Treatment of amyotrophic lateral sclerosis. Patent WO2021126320A1. Available at: https:\/\/patents.google.com\/patent\/WO2021126320A1\/en. Accessed 23 Jan 2024."},{"key":"3469_CR196","unstructured":"World Intellectual Property Organization. Liquid formulations of riluzole for oral and intravenous use. Patent WO2019108594A1. Accessed 23 Jan 2024."},{"key":"3469_CR197","unstructured":"MND Association. HEALEY ALS Platform Trial. Available at: https:\/\/www.mndassociation.org\/research\/clinical-trials\/treatment-trials\/healey-platform-trial. Accessed 29 Oct 2025."},{"key":"3469_CR198","doi-asserted-by":"publisher","unstructured":"Trial Working Group for the HEALEY ALS Platform Trial, Hayden D, Lai PY, et al. Pridopidine in amyotrophic lateral sclerosis: The HEALEY ALS platform trial. JAMA. 2025;333(13):1128\u20131137. https:\/\/doi.org\/10.1001\/JAMA.2024.26429.","DOI":"10.1001\/JAMA.2024.26429"},{"key":"3469_CR199","doi-asserted-by":"publisher","unstructured":"Trial Working Group for the HEALEY ALS Platform Trial, Hayden D, Lai PY, et al. Verdiperstat in amyotrophic lateral sclerosis: Results from the randomized HEALEY ALS platform trial. JAMA Neurol. 2025;82(4):333\u2013343. https:\/\/doi.org\/10.1001\/JAMANEUROL.2024.5249.","DOI":"10.1001\/JAMANEUROL.2024.5249"},{"key":"3469_CR200","unstructured":"Synapticure. Clinical trials for sporadic ALS. Available at: https:\/\/www.synapticure.com\/blog\/als-clinical-trials-amyotrophic-gehrig-fda-nurown-tregs-drugs-biologics. Accessed 28 Oct 2025."},{"key":"3469_CR201","unstructured":"Rethinking Clinical Trials. Pridopidine in ALS: Results from the HEALEY platform trial. Available at: https:\/\/rethinkingclinicaltrials.org\/news\/grand-rounds-april-11-2025-pridopidine-in-als-results-from-the-healey-platform-trial-jeremy-m-shefner-md-phd. Accessed 28 Oct 2025."},{"key":"3469_CR202","doi-asserted-by":"publisher","unstructured":"Paganoni S, Berry J, Quintana M, et al. Results from the first four regimens of the HEALEY ALS platform trial. Neurol. 2023;100(17_Supplement_2):4516. https:\/\/doi.org\/10.1212\/WNL.0000000000204032.","DOI":"10.1212\/WNL.0000000000204032"},{"issue":"4","key":"3469_CR203","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/JAMANEUROL.2024.5249","volume":"82","author":"J Andrews","year":"2025","unstructured":"Andrews J, Paganoni S, Macklin EA, et al. Verdiperstat in amyotrophic lateral sclerosis: Results from the randomized HEALEY ALS platform trial. JAMA Neurol. 2025;82(4):333. https:\/\/doi.org\/10.1001\/JAMANEUROL.2024.5249.","journal-title":"JAMA Neurol"},{"key":"3469_CR204","unstructured":"Labiotech. Thirteen companies developing new ALS treatments in 2025. Available at: https:\/\/www.labiotech.eu\/best-biotech\/als-companies\/. Accessed 28 Oct 2025."},{"key":"3469_CR205","doi-asserted-by":"publisher","unstructured":"Cudkowicz M, Drory V, Chi\u00f2 A, et al. Shifting the paradigm: PrimeC, an oral candidate for amyotrophic lateral sclerosis, demonstrates safety, efficacy, and target engagement in an 18-month phase 2b trial. Neurol. 2025;104(7_Supplement_1):3584. https:\/\/doi.org\/10.1212\/WNL.0000000000211098.","DOI":"10.1212\/WNL.0000000000211098"},{"key":"3469_CR206","unstructured":"ALS News Today. First-in-human trial of ALS therapy ASHA-624 expected in early 2025. Available at: https:\/\/alsnewstoday.com\/news\/first-human-trial-als-therapy-asha-624-expected-early-2025\/. Accessed 28 Oct 2025."},{"key":"3469_CR207","unstructured":"ClinicalTrials.gov. BrainGate2: Feasibility study of an intracortical neural interface system for persons with tetraplegia (NCT00912041). Available at: https:\/\/clinicaltrials.gov\/study\/NCT00912041. Accessed 28 Oct 2025."},{"key":"3469_CR208","unstructured":"Clinical Trials Arena. FDA lifts clinical hold on Neurizon\u2019s ALS drug. Available at: https:\/\/www.clinicaltrialsarena.com\/news\/fda-lifts-clinical-hold-on-neurizons-als-drug\/. Accessed 28 Oct 2025."},{"issue":"7","key":"3469_CR209","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1080\/14737175.2025.2508781","volume":"25","author":"F De Marchi","year":"2025","unstructured":"De Marchi F, Lombardi I, Bombaci A, et al. Recent therapeutic advances in the treatment and management of amyotrophic lateral sclerosis: The era of regenerative medicine. Expert Rev Neurother. 2025;25(7):773\u201389. https:\/\/doi.org\/10.1080\/14737175.2025.2508781.","journal-title":"Expert Rev Neurother"},{"key":"3469_CR210","doi-asserted-by":"publisher","unstructured":"Amado DA, Davidson BL. Gene therapy for ALS: A review. Molecul Therap. Published online 2021. https:\/\/doi.org\/10.1016\/j.ymthe.2021.04.008.","DOI":"10.1016\/j.ymthe.2021.04.008"},{"key":"3469_CR211","doi-asserted-by":"publisher","unstructured":"Lin TJ, Cheng GC, Wu LY, et al. Potential of cellular therapy for ALS: Current strategies and future prospects. Front Cell Develop Biol. Published online 2022. https:\/\/doi.org\/10.3389\/fcell.2022.851613.","DOI":"10.3389\/fcell.2022.851613"},{"key":"3469_CR212","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.omtm.2019.12.007","volume":"17","author":"AM Keeler","year":"2019","unstructured":"Keeler AM, Zieger M, Semple C, et al. Intralingual and intrapleural AAV gene therapy prolongs survival in a SOD1 ALS mouse model. Molecul Therap - Methods Clin Develop. 2019;17:246. https:\/\/doi.org\/10.1016\/j.omtm.2019.12.007.","journal-title":"Molecul Therap - Methods Clin Develop"},{"key":"3469_CR213","doi-asserted-by":"publisher","unstructured":"Chen HH, Yeo HT, Huang YH, et al. AAV-NRIP gene therapy ameliorates motor neuron degeneration and muscle atrophy in ALS model mice. Skeletal Muscle. 2024;14(1). https:\/\/doi.org\/10.1186\/S13395-024-00349-Z.","DOI":"10.1186\/S13395-024-00349-Z"},{"issue":"5","key":"3469_CR214","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1007\/S10072-025-07994-2","volume":"46","author":"AA Hamad","year":"2025","unstructured":"Hamad AA, Alkhawaldeh IM, Nashwan AJ, Meshref M, Imam Y. Tofersen for SOD1 amyotrophic lateral sclerosis: A systematic review and meta-analysis. Neurol Sci. 2025;46(5):1977. https:\/\/doi.org\/10.1007\/S10072-025-07994-2.","journal-title":"Neurol Sci"},{"issue":"1","key":"3469_CR215","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40035-025-00477-6","volume":"14","author":"Q Xie","year":"2025","unstructured":"Xie Q, Li K, Chen Y, Li Y, Jiang W, Cao W, et al. Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients. Transl Neurodegener. 2025;14(1):19.","journal-title":"Transl Neurodegener"},{"key":"3469_CR216","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.reth.2025.07.009","volume":"30","author":"H Khan","year":"2025","unstructured":"Khan H, Riaz H, Ahmed A, Kiyani MM, Jawad SM, Shah SSUD, et al. CRISPR\/Cas9 a genomic engineering technology for treatment in ALS mouse models. Regener Therap. 2025;30:575\u201383.","journal-title":"Regener Therap"},{"key":"3469_CR217","unstructured":"ALS Network. INS1202 Gene Therapy Shows Promise in SOD1-ALS Mice. 2025. https:\/\/alsnetwork.org\/mda-2025-ins1202-gene-therapy-shows-promise-in-sod1-als-mice\/. Accessed 9 Apr 2026."},{"key":"3469_CR218","doi-asserted-by":"publisher","first-page":"1675209","DOI":"10.3389\/fgene.2025.1675209","volume":"16","author":"SK Makkar","year":"2025","unstructured":"Makkar SK. Advances in RNA-based therapeutics: current breakthroughs, clinical translation, and future perspectives. Front Genet. 2025;16:1675209.","journal-title":"Front Genet"},{"issue":"1","key":"3469_CR219","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41591-019-0674-1","volume":"26","author":"M Bravo-Hernandez","year":"2020","unstructured":"Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26(1):118\u201330.","journal-title":"Nat Med"},{"issue":"12","key":"3469_CR220","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/mt.2013.211","volume":"21","author":"KD Foust","year":"2013","unstructured":"Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Mol Ther. 2013;21(12):2148\u201359.","journal-title":"Mol Ther"},{"key":"3469_CR221","doi-asserted-by":"crossref","unstructured":"Chen SK, Hawley ZCE, Zavodszky MI, Hana S, Ferretti D, Grubor B, Hawes M, et al. Efficacy and safety of a SOD1-targeting artificial miRNA delivered by AAV9 in mice are impacted by miRNA scaffold selection. Mol Therap Nucl Acids 2023:34.","DOI":"10.1016\/j.omtn.2023.102057"},{"key":"3469_CR222","doi-asserted-by":"crossref","unstructured":"Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, et al. Translating SOD1 gene silencing toward the clinic: a highly efficacious, off-target-free, and biomarker-supported strategy for fALS. Mol Therap Nucl Acids. 2018;12:75\u201388.","DOI":"10.1016\/j.omtn.2018.04.015"},{"key":"3469_CR223","doi-asserted-by":"publisher","unstructured":"Najafi S, Najafi P, Farkhad NK, et al. Mesenchymal stem cell therapy in amyotrophic lateral sclerosis (ALS) patients: A comprehensive review. Iranian J Basic Med Sci. Published online 2023. https:\/\/doi.org\/10.22038\/IJBMS.2023.66364.14572.","DOI":"10.22038\/IJBMS.2023.66364.14572"},{"key":"3469_CR224","doi-asserted-by":"publisher","unstructured":"Sironi F, De Marchi F, Mazzini L, Bendotti C. Cell therapy in ALS: An update on preclinical and clinical studies. Brain Res Bull. Published online 2023. https:\/\/doi.org\/10.1016\/j.brainresbull.2023.01.008.","DOI":"10.1016\/j.brainresbull.2023.01.008"},{"issue":"6","key":"3469_CR225","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1016\/J.YMTHE.2025.02.003","volume":"33","author":"W Lu","year":"2025","unstructured":"Lu W, Allickson J. Mesenchymal stromal cell therapy: Progress to date and future outlook. Mol Ther. 2025;33(6):2679\u201388. https:\/\/doi.org\/10.1016\/J.YMTHE.2025.02.003.","journal-title":"Mol Ther"},{"key":"3469_CR226","doi-asserted-by":"publisher","first-page":"107960","DOI":"10.1016\/J.PHRS.2025.107960","volume":"221","author":"M Shi","year":"2025","unstructured":"Shi M, Chu F, Zhu J. Stem cell therapy in neurodegenerative and neuroimmune diseases: Current status of treatments and future prospects. Pharmacol Res. 2025;221:107960. https:\/\/doi.org\/10.1016\/J.PHRS.2025.107960.","journal-title":"Pharmacol Res"},{"issue":"1","key":"3469_CR227","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13287-024-03765-6","volume":"15","author":"VK Harris","year":"2024","unstructured":"Harris VK, Stark J, Williams A, et al. Efficacy of intrathecal mesenchymal stem cell\u2013neural progenitor therapy in progressive multiple sclerosis: Results from a phase II, randomized, placebo-controlled clinical trial. Stem Cell Res Therap. 2024;15(1):1\u201314. https:\/\/doi.org\/10.1186\/S13287-024-03765-6.","journal-title":"Stem Cell Res Therap"},{"issue":"1","key":"3469_CR228","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3390\/BIOMEDICINES13010035","volume":"13","author":"L Frawley","year":"2024","unstructured":"Frawley L, Taylor NT, Sivills O, et al. Stem cell therapy for the treatment of amyotrophic lateral sclerosis: Comparison of the efficacy of mesenchymal stem cells, neural stem cells, and induced pluripotent stem cells. Biomedicines. 2024;13(1):35. https:\/\/doi.org\/10.3390\/BIOMEDICINES13010035.","journal-title":"Biomedicines"},{"issue":"7","key":"3469_CR229","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1007\/s42979-024-03205-5","volume":"5","author":"M Parmar","year":"2024","unstructured":"Parmar M, Patel HK. Time-Delay Control of UR5 Robot and Application in Telerobotic Ultrasound. SN Comput Sci. 2024;5(7):833. https:\/\/doi.org\/10.1007\/s42979-024-03205-5.","journal-title":"SN Comput Sci"},{"issue":"6","key":"3469_CR230","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/MACHINES12060415","volume":"12","author":"PK Lingampally","year":"2024","unstructured":"Lingampally PK, Ramanathan KC, Shanmugam R, Cepova L, Salunkhe S. Wearable assistive rehabilitation robotic devices\u2014A comprehensive review. Machines. 2024;12(6):415. https:\/\/doi.org\/10.3390\/MACHINES12060415.","journal-title":"Machines"},{"issue":"8","key":"3469_CR231","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1097\/PHM.0000000000002742","volume":"104","author":"KM Burke","year":"2025","unstructured":"Burke KM, Arulanandam V, Scirocco E, et al. Assistive technology in ALS: A scoping review of devices for limb, trunk, and neck weakness. Am J Phys Med Rehabil. 2025;104(8):e115\u201324. https:\/\/doi.org\/10.1097\/PHM.0000000000002742.","journal-title":"Am J Phys Med Rehabil"},{"issue":"1","key":"3469_CR232","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-62538-8","volume":"16","author":"J Arnold","year":"2025","unstructured":"Arnold J, Pathak P, Jin Y, et al. Personalized machine learning\u2013based wearable robot control improves impaired arm function. Nat Commun. 2025;16(1):1\u201314. https:\/\/doi.org\/10.1038\/s41467-025-62538-8.","journal-title":"Nat Commun"},{"issue":"9","key":"3469_CR233","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.3390\/IJMS26094346","volume":"26","author":"Y Kitaoka","year":"2025","unstructured":"Kitaoka Y, Uchihashi T, Kawata S, et al. Role and potential of artificial intelligence in biomarker discovery and development of treatment strategies for amyotrophic lateral sclerosis. Int J Mol Sci. 2025;26(9):4346. https:\/\/doi.org\/10.3390\/IJMS26094346.","journal-title":"Int J Mol Sci"},{"key":"3469_CR234","doi-asserted-by":"publisher","first-page":"446196","DOI":"10.3389\/FNEUR.2019.00291","volume":"10","author":"NS Verber","year":"2019","unstructured":"Verber NS, Shepheard SR, Sassani M, et al. Biomarkers in motor neuron disease: A state-of-the-art review. Front Neurol. 2019;10:446196. https:\/\/doi.org\/10.3389\/FNEUR.2019.00291.","journal-title":"Front Neurol"},{"key":"3469_CR235","doi-asserted-by":"publisher","first-page":"1608853","DOI":"10.3389\/FMOLB.2025.1608853","volume":"12","author":"F Anjum","year":"2025","unstructured":"Anjum F, Bakhuraysah M, Alsharif A, Mohammad T, Shamsi A, Hassan MI. Emerging biomarkers in amyotrophic lateral sclerosis: From pathogenesis to clinical applications. Front Mol Biosci. 2025;12:1608853. https:\/\/doi.org\/10.3389\/FMOLB.2025.1608853.","journal-title":"Front Mol Biosci"},{"issue":"5","key":"3469_CR236","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1097\/WCO.0000000000001411","volume":"38","author":"F Verde","year":"2025","unstructured":"Verde F. Neurochemical biomarkers of amyotrophic lateral sclerosis: Recent developments. Curr Opin Neurol. 2025;38(5):614\u20139. https:\/\/doi.org\/10.1097\/WCO.0000000000001411.","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"3469_CR237","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1093\/BRAIN\/AWAD075","volume":"146","author":"A Catanese","year":"2023","unstructured":"Catanese A, Rajkumar S, Sommer D, et al. Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis. Brain. 2023;146(9):3770\u201382. https:\/\/doi.org\/10.1093\/BRAIN\/AWAD075.","journal-title":"Brain"},{"key":"3469_CR238","doi-asserted-by":"publisher","unstructured":"Irwin KE, Sheth U, Wong PC, Gendron TF. Fluid biomarkers for amyotrophic lateral sclerosis: A review. Mol Neurodegener. Published online 2024. https:\/\/doi.org\/10.1186\/s13024-023-00685-6.","DOI":"10.1186\/s13024-023-00685-6"},{"issue":"20","key":"3469_CR239","doi-asserted-by":"publisher","first-page":"10900","DOI":"10.3390\/IJMS252010900","volume":"25","author":"RS Alshehri","year":"2024","unstructured":"Alshehri RS, Abuzinadah AR, Alrawaili MS, et al. A review of biomarkers of amyotrophic lateral sclerosis: A pathophysiologic approach. Int J Mol Sci. 2024;25(20):10900. https:\/\/doi.org\/10.3390\/IJMS252010900.","journal-title":"Int J Mol Sci"},{"key":"3469_CR240","doi-asserted-by":"publisher","unstructured":"Lanznaster D, Bejan-Angoulvant T, Patin F, et al. Plasma creatinine and amyotrophic lateral sclerosis prognosis: A systematic review and meta-analysis. Amyotrop Lateral Scleros Frontotemp Degener. Published online 2019. https:\/\/doi.org\/10.1080\/21678421.2019.1572192.","DOI":"10.1080\/21678421.2019.1572192"},{"key":"3469_CR241","doi-asserted-by":"publisher","unstructured":"Liu H, Lan S, Shi XJ, et al. Systematic review and meta-analysis on microRNAs in amyotrophic lateral sclerosis. Brain Res Bull. Published online 2023. https:\/\/doi.org\/10.1016\/j.brainresbull.2023.01.005.","DOI":"10.1016\/j.brainresbull.2023.01.005"},{"key":"3469_CR242","doi-asserted-by":"publisher","unstructured":"Behler A, M\u00fcller HP, Ludolph AC, Kassubek J. Diffusion tensor imaging in amyotrophic lateral sclerosis: Machine learning for biomarker development. Intern J Molecul Sci. 2023;24(3). https:\/\/doi.org\/10.3390\/IJMS24031911.","DOI":"10.3390\/IJMS24031911"},{"key":"3469_CR243","doi-asserted-by":"publisher","unstructured":"Lichtenstein T, Sprenger A, Weiss K, et al. MRI DTI and PDFF as biomarkers for lower motor neuron degeneration in ALS. Front Neurosci. Published online 2021. https:\/\/doi.org\/10.3389\/fnins.2021.682126.","DOI":"10.3389\/fnins.2021.682126"},{"key":"3469_CR244","doi-asserted-by":"publisher","unstructured":"Milella G, Sciancalepore D, Cavallaro G, et al. Acoustic voice analysis as a useful tool to discriminate different ALS phenotypes. Biomedicines. Published online 2023. https:\/\/doi.org\/10.3390\/biomedicines11092439.","DOI":"10.3390\/biomedicines11092439"},{"key":"3469_CR245","doi-asserted-by":"publisher","unstructured":"Kitaoka Y, Uchihashi T, Kawata S, et al. Role and potential of artificial intelligence in biomarker discovery and development of treatment strategies for amyotrophic lateral sclerosis. Intern J Mol Sci. 2025;26(9). https:\/\/doi.org\/10.3390\/IJMS26094346.","DOI":"10.3390\/IJMS26094346"},{"key":"3469_CR246","doi-asserted-by":"publisher","unstructured":"Grollemund V, Pradat PF, Querin G, et al. Machine learning in amyotrophic lateral sclerosis: Achievements, pitfalls, and future directions. Front Neurosci. 2019;13:135. https:\/\/doi.org\/10.3389\/FNINS.2019.00135.","DOI":"10.3389\/FNINS.2019.00135"},{"key":"3469_CR247","doi-asserted-by":"publisher","unstructured":"Tena A, Clari\u00e0 F, Solsona F, Povedano M. Voiceprint and machine learning models for early detection of bulbar dysfunction in ALS. Comput Methods Progr Biomed. Published online 2023. https:\/\/doi.org\/10.1016\/j.cmpb.2022.107309.","DOI":"10.1016\/j.cmpb.2022.107309"},{"key":"3469_CR248","doi-asserted-by":"publisher","first-page":"205520762513497","DOI":"10.1177\/20552076251349719","volume":"11","author":"H Qin","year":"2025","unstructured":"Qin H, Hussain L, Liu Z, et al. Optimizing deep learning models to combat amyotrophic lateral sclerosis disease progression. Digit Health. 2025;11:20552076251349720. https:\/\/doi.org\/10.1177\/20552076251349719.","journal-title":"Digit Health"},{"key":"3469_CR249","doi-asserted-by":"publisher","unstructured":"Straczkiewicz M, Karas M, Johnson SA, et al. Upper limb movements as digital biomarkers in people with ALS. eBioMedicine. Published online 2024. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105036.","DOI":"10.1016\/j.ebiom.2024.105036"},{"key":"3469_CR250","doi-asserted-by":"publisher","unstructured":"Papaiz F, Dourado MET, Valentim RA de M, de Morais AHF, Arrais JP. Machine learning solutions applied to amyotrophic lateral sclerosis prognosis: A review. Front Comput Sci. Published online 2022. https:\/\/doi.org\/10.3389\/fcomp.2022.869140.","DOI":"10.3389\/fcomp.2022.869140"},{"key":"3469_CR251","unstructured":"U.S. Food and Drug Administration. FDA releases action plan for rare neurodegenerative diseases, including ALS. Published online 2023. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-releases-action-plan-rare-neurodegenerative-diseases-including-als."},{"key":"3469_CR252","unstructured":"European Medicines Agency. PRIME: Priority medicines. 2018. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/prime-priority-medicines. Accessed 10 July 2025."},{"key":"3469_CR253","doi-asserted-by":"publisher","unstructured":"Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: Where are we now? Front Neurosci. Published online 2019. https:\/\/doi.org\/10.3389\/fnins.2019.01310.","DOI":"10.3389\/fnins.2019.01310"},{"key":"3469_CR254","doi-asserted-by":"publisher","unstructured":"Ly CV, Miller TM. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr Opin Neurol. Published online 2018. https:\/\/doi.org\/10.1097\/WCO.0000000000000594.","DOI":"10.1097\/WCO.0000000000000594"},{"key":"3469_CR255","unstructured":"Schultz J. Disease-modifying treatment of amyotrophic lateral sclerosis. Am J Managed Care. Published online 2018."},{"key":"3469_CR256","doi-asserted-by":"publisher","unstructured":"Vasques JF, Pinheiro LCT, de Jesus Gon\u00e7alves RG, Mendez-Otero R, Gubert F. Cell-based research and therapy for amyotrophic lateral sclerosis: Promises and challenges. Amyotr Lateral Scleros. Published online July 25, 2021:121\u2013139. https:\/\/doi.org\/10.36255\/EXONPUBLICATIONS.AMYOTROPHICLATERALSCLEROSIS.CELLTHERAPY.2021.","DOI":"10.36255\/EXONPUBLICATIONS.AMYOTROPHICLATERALSCLEROSIS.CELLTHERAPY.2021"},{"key":"3469_CR257","doi-asserted-by":"publisher","unstructured":"Mohamed LA, Markandaiah S, Bonanno S, Pasinelli P, Trotti D. Blood-brain barrier\u2013driven pharmacoresistance in amyotrophic lateral sclerosis and challenges for effective drug therapies. AAPS J. Published online 2017. https:\/\/doi.org\/10.1208\/s12248-017-0120-6.","DOI":"10.1208\/s12248-017-0120-6"},{"key":"3469_CR258","doi-asserted-by":"publisher","unstructured":"Wang GY, Rayner SL, Chung R, Shi BY, Liang XJ. Advances in nanotechnology-based strategies for the treatments of amyotrophic lateral sclerosis. Materials Today Bio. Published online 2020. https:\/\/doi.org\/10.1016\/j.mtbio.2020.100055.","DOI":"10.1016\/j.mtbio.2020.100055"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03469-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03469-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:03:42Z","timestamp":1790276622000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03469-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":258,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["3469"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03469-5","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that there is no conflict of interest regarding the publication of this review article.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"225"}}